Impact of prior thalidomide (T) therapy on the efficacy of pegylated liposomal doxorubicin (PLD) and bortezomib (B) in relapsed/refractory multiple myeloma (RRMM)

被引：0
|
作者：
Sonneveld, P.
Hajek, R.
Nagler, A.
Spencer, A.
Blade, J.
Robak, T.
Zhuang, S. H.
Harousseau, J. L.
Fruchtman, S.
Orlowski, R. Z.
机构：
[1] Erasmus MC, Rotterdam, Netherlands
[2] Interni Hematoonkol Klin Fak Brno, Brno, Czech Republic
[3] Chaim Sheba Med Ctr, Tel Hashomer, Israel
[4] Alfred Hosp, Melbourne, Vic, Australia
[5] Hosp Clin Barcelona, Barcelona, Spain
[6] Med Univ Lodz, Lodz, Poland
[7] J&J Pharmaceut Res & Dev LLC, Raritan, NJ USA
[8] Univ Hosp Hotel Dieu, Nantes, France
[9] Ortho Biotech Clin Affairs LLC, Bridgewater, NJ USA
[10] Univ N Carolina, Chapel Hill, NC 27515 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2007年 / 25卷 / 18期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
8023
引用
收藏
页数：2
相关论文
共 50 条
  • [21] The prolonged time to progression with pegylated liposomal doxorubicin plus bortezomib versus bortezomib alone in relapsed or refractory multiple myeloma is unaffected by extent of prior therapy or previous anthracycline exposure
    Blade, Joan
    Miguel, Jesus San
    Nagler, Amon
    Sonneveld, Pieter
    Spencer, Andrew
    Robak, Tadeusz
    Hennessey, Kathleen
    Mundle, Suneel D.
    Zhuang, Sen H.
    Harousseau, Jean-Luc
    Drlowski, Robert Z.
    [J]. BLOOD, 2007, 110 (11) : 127A - 127A
  • [22] Bortezomib/pegylated liposomal doxorubicin combinations in multiple myeloma
    Reddy, GK
    D'Orazio, A
    [J]. CLINICAL LYMPHOMA & MYELOMA, 2005, 6 (03): : 170 - 171
  • [23] BORTEZOMIB, PEGYLATED LIPOSOMAL DOXORUBICIN AND DEXAMETHASONE (B-D-D) AS THERAPY FOR ELDERLY PATIENTS WITH RELAPSED REFRACTORY MULTIPLE MYELOMA: A WEEKLY BORTEZOMIB SCHEDULE REDUCES TOXICITIES MANTAINING THE SAME EFFICACY
    Gozetti, A.
    Fabbri, A.
    Marchini, E.
    Oliva, S.
    Defina, M.
    Bocchia, M.
    Lauria, F.
    [J]. HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2009, 94 : 156 - 156
  • [24] Lenalidomide and pegylated liposomal doxorubicin-based chemotherapy for relapsed or refractory multiple myeloma: safety and efficacy
    Baz, R.
    Walker, E.
    Karam, M. A.
    Choueiri, T. K.
    Jawde, R. A.
    Bruening, K.
    Reed, J.
    Faiman, B.
    Ellis, Y.
    Brand, C.
    Srkalovic, G.
    Andresen, S.
    Knight, R.
    Zeldis, J.
    Hussein, M. A.
    [J]. ANNALS OF ONCOLOGY, 2006, 17 (12) : 1766 - 1771
  • [25] Total costs of therapy with lenalidomide or bortezomib in relapsed/refractory multiple myeloma (rrMM).
    Borrello, Ivan
    Binder, Gary
    Khan, Zeba M.
    Pashos, Chris L.
    Durie, Brian G.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [26] BORTEZOMIB IN COMBINATION WITH PEGYLATED LIPOSOMAL DOXORUBICIN AND THALIDOMIDE (VDT) FOR THE TREATMENT OF PREVIOUSLY UNTREATED MULTIPLE MYELOMA
    Ailawadhi, S.
    Miller, K. C.
    Depaolo, D.
    Whitworth, A.
    Yu, J.
    Trump, D. L.
    Padmanabhan, S.
    Czuczman, M.
    Bernstein, Z. P.
    Hernandez-Ilizaliturri, F.
    Lee, K.
    Chanan-Khan, A.
    [J]. HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2008, 93 : 83 - 83
  • [27] Bortezomib in combination with pegylated liposomal doxorubicin and thalidomide (VDT) for the treatment of previously untreated multiple myeloma
    Chanan-Khan, Asher A.
    Miller, Kena C.
    DePaolo, Dawn
    Padmanabhan, Swaminathan
    Whitworth, Amy
    Ailawadhi, Sikander
    Lee, Kelvin
    Czuczman, Myron S.
    [J]. BLOOD, 2007, 110 (11) : 1057A - 1058A
  • [28] Vorinostat in Combination with Pegylated Liposomal Doxorubicin and Bortezomib for Patients with Relapsed/Refractory Multiple Myeloma: Results of a Phase I Study
    Voorhees, Peter M.
    Gasparetto, Cristina
    Richards, Kristy L.
    Garcia, Reynaldo
    Strader, John S.
    Ferraro, Madlyn
    MacLean, Jennifer
    Winans, Diane
    Moore, Dominic T.
    Dodd, Andrew
    Foster, Matthew C.
    Gabriel, Don A.
    Shea, Thomas C.
    Serody, Jonathan
    van Deventer, Hendrik W.
    Rizvi, Syed
    Orlowski, Robert Z.
    Hurd, David D.
    [J]. BLOOD, 2009, 114 (22) : 129 - 130
  • [29] A modified regimen of pegylated liposomal doxorubicin, bortezomib, and dexamethasone is effective and well tolerated in the treatment of relapsed or refractory multiple myeloma
    Gabriel N. Waterman
    Ori Yellin
    Regina A. Swift
    Russell Mapes
    Benjamin Eades
    Emily Ackerman
    James R. Berenson
    [J]. Annals of Hematology, 2011, 90 : 193 - 200
  • [30] A modified regimen of pegylated liposomal doxorubicin, bortezomib, and dexamethasone is effective and well tolerated in the treatment of relapsed or refractory multiple myeloma
    Waterman, Gabriel N.
    Yellin, Ori
    Swift, Regina A.
    Mapes, Russell
    Eades, Benjamin
    Ackerman, Emily
    Berenson, James R.
    [J]. ANNALS OF HEMATOLOGY, 2011, 90 (02) : 193 - 200
12345